SCHEMBL255803

SCHEMBL255803

CC(=O)NC(C)(C)Cc1ccc(I)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.52
ALDH1A1 P00352 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
RECQL P46063 1/20 0.39
OPRM1 P35372 2/20 0.37
OPRD1 P41143 2/20 0.37
OPRK1 P41145 2/20 0.37
HPGD P15428 1/20 0.37
MMP8 P22894 1/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
BLM P54132 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21160945 0.91 ACACB (0.59) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL1998840 0.86 CYP3A4 (0.49) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL3640956 0.84 ACACB (0.54) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL564817 0.84 ACACB (0.57) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6621894 0.82 ACACB (0.52) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL8384266 0.82 KDM4E (0.53) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6514301 0.81 ALDH1A1 (0.65) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6540252 0.81 ALDH1A1 (0.45) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL255661 0.80 PTPRB (0.41) ACACBALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL564559 0.79 ACACB (0.50) ACACBALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 EP disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
WO-2012028676-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof ABCG2, PGA5, PDE6G ACACB 2257/4885ALDH1A1 1739/4885CYP3A4 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.